EGFR Targeted Therapy
EGFR targeted therapy blocks signals from the epidermal growth factor receptor (EGFR), a protein that controls cell growth, and is an important option in colorectal cancer treatment in Malaysia. When EGFR mutates, it causes uncontrolled cancer growth, especially in non-small cell lung cancer (NSCLC).
Mutations in the EGFR gene make EGFR overactive and drive cancer growth. Targeted therapies block this overactivity, shrink tumors, and provide a more effective, less harmful alternative to chemotherapy.
Understanding EGFR Targeted Therapy
EGFR targeted therapy takes a revolutionary approach to treating cancers caused by mutations in the epidermal growth factor receptor (EGFR).
The EGFR protein, located on the surface of cells, plays a key role in controlling cell growth. When the EGFR gene mutates, it triggers uncontrolled cancer cell division, especially in non-small cell lung cancer (NSCLC).
This therapy targets and blocks the signals from the mutated EGFR protein, slowing down or stopping cancer cell growth.
Unlike traditional chemotherapy, which attacks both cancerous and healthy cells, EGFR targeted therapy focuses only on the cancer cells with the mutated EGFR. This precision reduces damage to healthy tissues nearby.
Why Choose OncoLife Centre for EGFR Targeted Therapy?
Expertise with EGFR-Positive Cancers
OncoLife Centre’s oncology specialists have extensive experience in treating cancers driven by EGFR mutations. Whether you’re newly diagnosed or dealing with a resistant case, our team provides cutting-edge treatments tailored to each patient’s specific needs.
Access to the Latest Clinical Trials
Our patients can participate in clinical trials that improve EGFR-targeted therapies. These trials test new approaches and offer hope for more effective treatments.
Personalized Care
At OncoLife Centre, we understand that every patient’s cancer is unique. We create personalized treatment plans that are based on the specific EGFR mutation, the cancer’s stage, and the individual’s treatment preferences. This approach ensures the best possible outcomes for our patients.
Key Benefits of EGFR Targeted Therapy
EGFR targeted therapy offers numerous advantages for patients with EGFR-positive cancers. This section highlights some of the most important benefits that make this treatment a game-changer in cancer care.
Precision Targeting of Cancer Cells
One of the primary benefits of EGFR targeted therapy is its precision in targeting cancer cells with EGFR mutations.
Unlike traditional chemotherapy, which can affect both cancerous and healthy cells, EGFR targeted therapy is designed to specifically attack cancer cells that have the mutated EGFR protein.
This targeted approach minimizes damage to normal tissues, sparing healthy cells and reducing the side effects typically associated with chemotherapy.
This makes it a more effective and safer treatment option, especially for patients who require long-term treatment.
Reduced Side Effects
Another key advantage of EGFR targeted therapy is its relatively mild side effect profile. Chemotherapy is well known for causing severe side effects such as nausea, hair loss, fatigue, and immune system suppression.
In contrast, EGFR targeted therapy tends to cause fewer and less intense side effects, such as skin rashes, diarrhea, and mild fatigue. While these side effects can still be bothersome, they are generally more manageable than the side effects of chemotherapy, allowing many patients to continue their daily activities with less disruption.
Improved Overall Survival
Studies have consistently shown that EGFR targeted therapies, significantly improve overall survival for patients with EGFR-positive cancers. By inhibiting the overactive EGFR signaling pathway, these therapies slow down cancer progression and can even shrink tumors.
For patients with early-stage cancers like non-small cell lung cancer (NSCLC), these therapies offer the potential for a longer survival rate and a better quality of life. The ability to block the abnormal signaling that drives cancer growth allows patients to enjoy more time with their loved ones, free from the constant burden of rapidly progressing cancer.
Personalized Treatment Options
EGFR targeted therapies are uniquely personalized based on each patient’s specific EGFR mutation. This means that treatment is tailored to target the exact genetic changes causing the cancer, ensuring that the therapy is as effective as possible. Unlike one-size-fits-all approaches, personalized treatment with EGFR-targeted therapies maximizes the chance for a positive outcome, helping to eliminate the cancer more efficiently while minimizing unnecessary treatments.
This personalized approach also allows oncologists to adjust therapy based on the patient’s response, providing a more dynamic and adaptable treatment plan.
First-Line Treatments That Target EGFR
Doctors usually start treatment for EGFR-positive cancers with a first-line therapy approved by the Food and Drug Administration (FDA). These treatments often include drugs that target the EGFR protein and work alone or with other therapies like chemotherapy. First-line therapies can greatly improve survival and help control cancer growth.
How Targeted Therapy Helps EGFR-Positive Patients
Targeted therapy gives a more effective option than traditional treatments, especially for patients with EGFR mutations. This approach blocks the specific pathways that cause the cancer to grow, offering patients a better chance of longer survival and a higher quality of life.
Dealing with Resistance to EGFR Targeted Therapies
While EGFR targeted therapies have proven effective, some patients may develop resistance over time.
This resistance occurs when cancer cells mutate further and find ways to bypass the effects of the drugs.
Some common mechanisms of resistance include the development of new mutations in the EGFR gene, the activation of alternative growth pathways, or even the transformation of the cancer into a more aggressive form like small cell lung cancer.
Adapting Treatment After Resistance Develops
When resistance occurs, doctors may adjust the treatment plan by switching to newer drugs or combining therapies.
These adjustments are crucial in maintaining the effectiveness of treatment and ensuring that patients continue to receive the most appropriate care for their condition.
Side Effects of EGFR Targeted Therapy
Like all cancer treatments, EGFR targeted therapies come with potential side effects. However, these side effects tend to be milder compared to those experienced with traditional chemotherapy. Common side effects include skin rashes, diarrhea, fatigue, and mouth sores. The rash is often an indicator that the drug is working to block the EGFR receptor, and while it can be bothersome, it typically resolves with appropriate management.
It’s important for patients to discuss any side effects they experience with their healthcare team. Early intervention can help manage these symptoms effectively, allowing patients to stay on therapy for longer periods and improving their chances of better outcomes.
Hope Through EGFR Targeted Therapy
EGFR targeted therapy represents a significant advancement in cancer treatment, offering a more precise and effective approach to managing EGFR-positive cancers. With targeted drugs, patients experience fewer side effects and often see better responses than with traditional chemotherapy. At OncoLife Centre, we are dedicated to providing the best possible care, utilizing the latest treatments, offering access to clinical trials, and ensuring that every patient receives personalized attention.
If you or a loved one is living with EGFR-positive cancer, contact OncoLife Centre today to learn more about how EGFR targeted therapy can help you on your journey to recovery.
Your Journey
Start Your Recovery
Our dedicated Patient Navigator will assist you with appointment scheduling. Contact us at +6012-3993260 (Call or Whatsapp ).
First Consultation
On appointment day, bring along all the medical reports and your identity documents, ie. identity card or passport. Our team will help you organize the medical reports for our oncologist to review. Our oncologist will discuss the treatment plan with you. Tele-consult is available for overseas patients.
Treatment Day
Come to our center on an agreed date and time for the treatment. Our team will take good care of you. You will be discharged on the same day. Yes, you will get to go home after every treatment visit as no overnight admission is required.
Stay on Track
Our dedicated patient navigator will be following up with you post treatment to check on your condition, to ensure that you are doing well. You will receive a reminder message on your phone for the next appointment date.
Hello, I’m Dr. Christina Ng Van Tze, a Consultant Medical Oncologist and Medical Director at Onco Life Centre, as well as the Founder President of Empowered The Cancer Advocacy Society of Malaysia. Throughout my career, I have been passionate about advancing personalized cancer treatment, strengthening community advocacy, and expanding access to high-quality care for patients across Malaysia.
Attending the ESMO Congress 2025 in Berlin was both inspiring and energizing. Representing Onco Life Centre, our dedicated medical centre in Malaysia, I stood among global leaders committed to shaping the future of oncology. This year’s congress was filled with remarkable scientific breakthroughs, thoughtful discussions, and a renewed sense of purpose as we work toward better outcomes and better lives for our patients.
A Global Gathering Focused on Precision Cancer Care
ESMO 2025 brought together thousands of clinicians, researchers, and advocates from around the world. What made this year particularly exciting was the strong emphasis on precision medicine, from cancer genetics and molecular profiling to advanced imaging and AI-powered diagnostic tools. These advancements are aligning closely with the work we do at Onco Life Centre, where patient individuality and tumor biology guide our treatment decisions.
Throughout the congress, many experts highlighted the importance of understanding each patient’s tumor in greater depth. Whether through genomic sequencing, circulating tumor DNA, or radiomic analyses, the oncology community is moving firmly toward personalized strategies. As someone who has long championed individualized care, I found these sessions especially meaningful.
Key Scientific Sessions That Inspired Me
One of the standout presentations was the evERA BC trial, a major study evaluating the combination of giredestrant, an oral SERD, with an mTOR inhibitor drug in hormone receptor-positive breast cancer. The results showed a significant improvement in progression-free survival, especially in tumors driven by ESR1 mutations. For patients who have progressed on CDK4/6 inhibitors, this combination may become an essential addition to our treatment toolbox.
This study also supports a larger movement within oncology—creating thoughtful, layered treatment plans that address resistance pathways and extend the time patients can remain on endocrine-based therapies. It’s a direction that can profoundly benefit Malaysian women, many of whom are diagnosed at younger ages or have aggressive tumor profiles.
Insights from the thoracic oncology sessions were equally impactful. Advances in lung cancer, including AI-driven pathology models, updated ALK-targeted treatment strategies, and ctDNA-guided therapy adjustments, reminded me just how quickly this field is evolving. Given the increasing prevalence of lung cancer in Malaysia, especially among non-smokers and women, these developments hold tremendous value for our community.
The Role of AI in Transforming Clinical Practice
One major theme across the congress was the integration of artificial intelligence into clinical decision-making. Researchers demonstrated how AI models can analyze pathology slides, radiology images, and genomic data to predict which patients are more likely to respond to immunotherapy or targeted treatment. These tools help us avoid ineffective therapies and guide patients toward options with the most tremendous potential.
At Onco Life Centre, we have been exploring the use of digital technologies to streamline assessments and enhance patient monitoring. Seeing the global oncology community embrace these tools assures me that we are moving in the right direction. I hope that AI will continue to improve early detection, refine treatment selection, and ultimately support better survival outcomes for Malaysian patients.
Representing Onco Life Centre on the International Stage
Representing Onco Life Centre at an event of this scale was a true honor. Our centre has always focused on delivering holistic, science-driven care, and it was wonderful to share our experiences with colleagues from around the world. I had meaningful conversations about challenges related to access to molecular testing globally, variability in treatment availability, and the need for stronger psycho-oncology support systems.
These interactions not only validated the work we do but also highlighted areas where we can continue to grow. Bringing international insights back to Malaysia ensures that our patients benefit from the same cutting-edge thinking shaping care in Europe, America, and beyond.
Bringing ESMO Insights Home to Malaysia
Returning from Berlin, I feel a renewed commitment to integrating the latest research into our daily practice. In the coming months, we aim to:
- Enhance our use of molecular profiling for breast, lung, and gastrointestinal cancers
- Expand ctDNA testing where appropriate to guide treatment decisions
- Strengthen multidisciplinary discussions for complex cases
- Continue investing in supportive care and psycho-oncology services
- Provide patients and families with clearer, more personalized education about treatment choices
As a clinician, I believe that every advancement, no matter how technical, must ultimately translate into compassionate, human-centered care. This balance of science and empathy remains at the core of our mission.
A Future of Hope and Collaboration
ESMO 2025 reaffirmed what I’ve always believed: oncology is advancing rapidly, but meaningful progress relies on collaboration, continuous learning, and a deep commitment to patient care. I’m genuinely grateful for the opportunity to represent Onco Life Centre on this global platform. Being part of these critical conversations strengthens our mission to raise the standard of oncology in Malaysia. It ensures our patients benefit from the latest, most effective innovations in cancer care.
Moving forward, we will continue engaging with global partners, conducting meaningful advocacy through Empowered, and ensuring our patients receive the highest standard of personalized treatment.
Together, we can build a future where every individual facing cancer feels seen, supported, and empowered.
Onco Life Centre Wins 2025 Best Oncology Clinic in Malaysia
We are proud to share that Onco Life Centre has been named the Oncology Clinic and Treatment Centre of the Year in Malaysia at the GlobalHealth Asia-Pacific Awards 2025, held in Bangkok.
This prestigious recognition is a testament to our unwavering commitment to delivering personalized, compassionate, and cutting-edge cancer care to our patients. The award reflects not just our clinical excellence, but our dedication to safety, community outreach, and innovation in oncology services.
The GlobalHealth Asia-Pacific Awards celebrate leading healthcare institutions across the region. Winners are chosen based on a comprehensive evaluation of criteria such as:
Excellence and Innovation: Transforming healthcare delivery and patient outcomes through progressive medical practices.
Patient Safety: Upholding the highest standards to ensure safe, comfortable, and effective treatment environments.
Community Involvement: Actively engaging in public awareness, screening programs, and care for underprivileged communities.
Technology Adoption: Integrating advanced diagnostics, therapies, and digital tools to enhance every aspect of care.
Impact and Measurable Results: Demonstrating tangible improvements in cancer detection, treatment success, and patient well-being.
Adaptability and Preparedness: Being resilient and forward-thinking in the face of global health challenges.
Leadership and Vision: Cultivating a culture that prioritizes empathy, innovation, and ongoing education.
This award inspires us to continue raising the bar in oncology care—not only through medical advancements but by remaining deeply rooted in our advocacy mission: to serve, educate, and empower every cancer patient, especially those most in need.
We dedicate this achievement to our patients, survivors, caregivers, and the entire Onco Life Centre community. Your courage fuels our purpose. Together, we will continue the fight—because every life matters.
NSCLC (Non-small cell lung cancer)
2010 Breast and Lung Cancer Awareness Campaign (LEMBAH PANTAI)
2011 Colorectal Cancer Screening and Treatment Community Project (GOMBAK AND SELAYANG)
2011 & 2012 Colorectal Cancer Awareness, Screening and Treatment Community Project (SETAPAK)
2012 Colorectal Cancer Screening and Treatment Community Project (LEMBAH SUBANG)
2014 Colorectal Cancer Awareness, Screening and Treatment Community Project (CHERAS)
2015 Colorectal Cancer Awareness, Screening and Treatment Project (HILIRAN AMPANG)
2016 Colorectal Cancer Awareness, Screening and Treatment Project (DESA TUN RAZAK)
Credentials You Can Trust
Ministry of Health Malaysia
Onco Life Centre is fully licensed as an Oncology Consultation and Treatment Centre (License No: 931401-00214-03/2024)
DR. CHRISTINA NG VAN TZE
CONSULTANT MEDICAL ONCOLOGIST (NSR: 131550)
MBBS (MELB), FELLOW RACP (AUS)
DR. JOSEPH KANIANTHRA JOSEPH
CONSULTANT MEDICAL ONCOLOGIST (NSR: 124660)
MBBCH, BAO (IRE), MRCP (UK)
Service Area
Onco Life Centre location
Download our booklet
about Colorectal cancer for FREE
